New milestone as LCT and OptiCellAI advance AI for NTCELL's manufacture
New milestone as LCT and OptiCellAI advance AI for NTCELL's manufacture, as part of LCT's third clinical trial of NTCELL in Parkinson's disease.
Receipt of Section 249D Notice
Living Cell Technologies has received a notice pursuant to Section 249D of the Corporations Act 2001.
Becoming a substantial holder
Notice of initial substantial holder for Living Cell Technologies (ASX:LCT).
Change of Director's Interests Notice - R Willcocks
Change of Director's Interest Notice for LCT Director Robert Willcocks, who has acquired an additional 500,000 ordinary shares in LCT.
Notification regarding unquoted securities - LCT
Living Cell Technologies provides notification of the issue of unlisted options under an employee incentive scheme.